Click to Share
 
 
  1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution
Filter News
Show All Results
News By Country
News By Tag
Rare Diseases Remove


October 2014
Fr Th We Tu Mo Su Sa
24 23 22 21 20 19 18

rare diseases Press Releases

  + XML/RSS  



By Visiongain
London, UK, 14th October 2014: A new report by visiongain calculates that the molecular diagnostics market will reach $6.13bn in 2014 with revenue showing high overall growth to 2024.

By SMi Group Ltd
SMi is proud to have Dr. Günter Harms, Market Access & Public Affairs Director at Shire, giving the opening address at this year’s Orphan Drugs and Rare Diseases conference taking place in London on October 20th and 21st 2014.

By SMi Group Ltd
SMi reports: According to Rare Disease UK, research and development in the area of rare diseases can often provide further understanding and insight into more common diseases.

By Clinigen Group
Panel of industry experts chaired by SVP Clinigen Global Access Programs offers best practices for programs enabling access for patients with unmet medical needs

By SMi Group Ltd
SMi is proud to have Dr. Günter Harms, Market Access & Public Affairs Director at Shire, giving the opening address at this year’s Orphan Drugs and Rare Diseases conference taking place in London on October 20th and 21st 2014.

By SMi Group Ltd
SMi Reports: Britain was looking to accelerate access to drugs for patients with rare diseases when it launched the Early Access to Medicines Initiative in March this year. This initiative will be extremely beneficial for patients.

By SMi Group Ltd
As of January 2014, the EMA lifted the restriction on providing fee reductions to large companies developing new orphan drugs and the Early Access to Medicines Scheme was introduced.

By o2 mediainc.com
Special Edition airing February 28th, World Rare Disease Day focuses on raising awareness and offering hope and support for Rare Disease Community as part of the “Behind the Mystery: Rare and Genetic Diseases” series

By SMi Group
Pfizer, GlaxoSmithKline, Novo Nordisk, Findacure Foundation and many others will meet in London at SMi’s 2nd Annual Orphan Drugs & Rare Diseases Conference to share their best practices.

By Rochelle Weinstein
With the widespread acclaim of her debut novel, WHAT WE LEAVE BEHIND, Rochelle B. Weinstein has won the hearts of readers worldwide.

All Press Releases

By Visiongain
London, UK, 14th October 2014: A new report by visiongain calculates that the molecular diagnostics market will reach $6.13bn in 2014 with revenue showing high overall growth to 2024.

By SMi Group Ltd
SMi is proud to have Dr. Günter Harms, Market Access & Public Affairs Director at Shire, giving the opening address at this year’s Orphan Drugs and Rare Diseases conference taking place in London on October 20th and 21st 2014.

By SMi Group Ltd
SMi reports: According to Rare Disease UK, research and development in the area of rare diseases can often provide further understanding and insight into more common diseases.

By Clinigen Group
Panel of industry experts chaired by SVP Clinigen Global Access Programs offers best practices for programs enabling access for patients with unmet medical needs

By SMi Group Ltd
SMi is proud to have Dr. Günter Harms, Market Access & Public Affairs Director at Shire, giving the opening address at this year’s Orphan Drugs and Rare Diseases conference taking place in London on October 20th and 21st 2014.

By SMi Group Ltd
SMi Reports: Britain was looking to accelerate access to drugs for patients with rare diseases when it launched the Early Access to Medicines Initiative in March this year. This initiative will be extremely beneficial for patients.

By SMi Group Ltd
As of January 2014, the EMA lifted the restriction on providing fee reductions to large companies developing new orphan drugs and the Early Access to Medicines Scheme was introduced.

By o2 mediainc.com
Special Edition airing February 28th, World Rare Disease Day focuses on raising awareness and offering hope and support for Rare Disease Community as part of the “Behind the Mystery: Rare and Genetic Diseases” series

By SMi Group
Pfizer, GlaxoSmithKline, Novo Nordisk, Findacure Foundation and many others will meet in London at SMi’s 2nd Annual Orphan Drugs & Rare Diseases Conference to share their best practices.

By Rochelle Weinstein
With the widespread acclaim of her debut novel, WHAT WE LEAVE BEHIND, Rochelle B. Weinstein has won the hearts of readers worldwide.

By NTSAD
First human trial for Tay-Sachs, Canavan and other rare enzyme deficiency diseases plans to begin in early 2013 thanks to NTSAD, the nation's oldest patient advocacy organization, which leads efforts to find a cure or treatment.

By American Conference Institute
ACI introduces its Guide to Orphan Drugs and Rare Diseases: Maximizing Opportunities and Overcoming Stumbling Blocks in the Designation and Development Process.

By Mary Ann Liebert, Inc., publishers
A clinically challenging and under-studied subset of diseases affecting the lymphatic system and grouped under the disease spectrum lymphangiomatosis and Gorham’s disease is the focus of a special issue of Lymphatic Research and Biology.

By Michele Westergaard
Citing the existence of over 6,000 rare diseases Joff Masukawa, Senior Director, Government Relations and Public Policy, Shire details his role in orphan product development and explains the importance of early engagement.

By Michele Westergaard
Conference Brings Together Industry Leaders to Overcome Commercialization Challenges and Enhance Patient Access to Orphan Drugs

By Jacqueline Tanzella
Campaign Brings Together Support from over 90 Corporations, Non-Profit Foundations, Research Institutions, Hospitals and Advocacy Groups; New Blue Jeans Denim Ribbon Unveiled To Promote Rare Disease Awareness

By Uplifting Athletes, Inc.
The Penn State Football Uplifting Athletes fifth annual Lift For Life® event was a tremendous success.



Page updated every 10 minutes


  1. SiteMap
  2. Contact PRLog
  3. Privacy Policy
  4. Terms of Service
  5. Copyright Notice
  6. About
  7. Advertise
Like PRLog?
9K2K1K
Click to Share